Quarterly report pursuant to Section 13 or 15(d)
Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
---|---|---|
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Amendment Flag | false | |
Document Period End Date | Sep. 30, 2020 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q3 | |
Document Transition Report | false | |
Entity File Number | 001-34079 | |
Entity Registrant Name | REXAHN PHARMACEUTICALS, INC. | |
Entity Central Index Key | 0001228627 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 11-3516358 | |
Entity Address, Address Line One | 15245 Shady Grove Road | |
Entity Address, Address Line Two | Suite 455 | |
Entity Address, City or Town | Rockville | |
Entity Address, State or Province | MD | |
Entity Address, Postal Zip Code | 20850 | |
City Area Code | 240 | |
Local Phone Number | 268-5300 | |
Title of 12(b) Security | Common Stock, $.0001 par value | |
Trading Symbol | REXN | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Shell Company | false | |
Entity Emerging Growth Company | false | |
Entity Common Stock, Shares Outstanding | 4,483,198 |
Attachments
- Original document
- Permalink
Disclaimer
Rexahn Pharmaceuticals Inc. published this content on 29 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 October 2020 13:44:08 UTC